Important note: Information in this article was accurate in 2002. The state of the art may have changed since the publication date.
PRNewswire - November 25, 2002
The conference assembles leading AIDS researchers worldwide at its annual meeting.
Hemispherx focuses on the development of nucleic acids to enhance anti-viral defense systems. It is the leading company in the experimental-stage development of immune-based therapies primarily addressing the diseases of HIV/AIDS and Chronic Fatigue Syndrome. HIV DART is one of the leading international conferences focusing on antiretroviral research and HIV.
The article, "A Phase IIB Prospective, Randomized, Controlled Study Evaluating the Immunomodulatory Role of Poly I:Poly C12U Against HIV During STI," will discuss new interim results from the ongoing study in eight sites around the country. Earlier peer review data suggested a median of more than 27 weeks off HIV therapy medications without significant viral rebound, compared with seven weeks in patients undergoing STI without Ampligen(R).
Without interrupted treatment, HIV medications may lead to multi-drug resistance due to viral mutations as well as unacceptable long-term toxicity.
Hemispherx Biopharma, based in Philadelphia, is a bio-pharmaceutical company engaged in the manufacture and global clinical development of new drug entities in the nucleic acid (NA) class for chronic viral diseases and disorders of the immune system including, HIV, CFS and Hepatitis. Its platform technology includes large and small agent components for potential treatment of various chronic viral infections. For more information visit the company's Web site at http://www.hemispherx.net.
Information contained in this news release other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risk of competition, changing market conditions, change in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company's filings with the Securities and Exchange Commission. Accordingly, all the referenced investigational drugs and associated technologies of the company are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements.
SOURCE Hemispherx Biopharma
Web Site: http://www.hemispherx.net
021125
PR021138
Copyright © 2002 - PRNewswire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through PRNewswire, Permissions, 810 Seventh Ave., 32nd Floor, New York, NY 10019 http://www.prnewswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2002. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2002. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .